Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
176 hedge funds and large institutions have $2.41B invested in Global Blood Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 63 increasing their positions, 54 reducing their positions, and 27 closing their positions.
78% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 27
74% more call options, than puts
Call options by funds: $56.3M | Put options by funds: $32.2M
41% more capital invested
Capital invested by funds: $1.71B → $2.41B (+$697M)
17% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 54
12% more funds holding
Funds holding: 157 → 176 (+19)
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$124M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$91.1M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$37.5M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$34.7M |
| 5 |
Renaissance Technologies
New York
|
+$34.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$38.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$37.2M |
| 3 |
Millennium Management
New York
|
-$19.5M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$14.2M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$13.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
S
201
SignatureFD
Atlanta,
Georgia
| – | +$112 | +2 | New |
|
202
CIBC Private Wealth Group
Atlanta,
Georgia
| – | +$390 | +7 | New |
|
GBT Hedge Fund Activity: Q1 2018 in Review
176 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q1 2018, worth a combined $2.41B — up 41% from $1.71B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new GBT positions and 27 closed out — a net gain of 21 holders — while 63 added to existing stakes and 54 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $124M. The largest seller was OrbiMed, cutting an estimated $38.6M.
- 176 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q1 2018, up from 157 in Q4 2017.
- Funds reported $2.41B of Global Blood Therapeutics, Inc. stock for Q1 2018, up 41% quarter-over-quarter.
- 48 funds opened new Global Blood Therapeutics, Inc. positions in Q1 2018 and 27 closed out, a net change of +21 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q1 2018 was Wellington Management Group, an estimated $124M added.
- The largest Global Blood Therapeutics, Inc. seller in Q1 2018 was OrbiMed, an estimated $38.6M sold.
Based on aggregated 13F filings for Q1 2018.